<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-5500-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KETESSE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEXKETOPROFEN TROMETHAMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate and solvent for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="A MENARINI INDUSTRIE FARMACEUTICHE S.R.L" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            A MENARINI INDUSTRIE FARMACEUTICHE S.R.L
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            A MENARINI INDUSTRIE FARMACEUTICHE S.R.L
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AE17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ketesse is a pain killer from the group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).</p><p>It is used to treat acute moderate to severe pain, when taking tablets is not appropriate, such as post-operative pain, renal colic (severe kidney pain) and low back pain.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not use Ketesse:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to dexketoprofen or any of the other ingredients of this medicine (listed in section 6);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to acetylsalicylic acid or to other non-steroidal anti-inflammatory medicines;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have asthma or have suffered attacks of asthma, acute allergic rhinitis (a short period of inflamed lining of the nose), nasal polyps (lumps within the nose due to allergy), urticaria (skin rash), angioedema (swollen face, eyes, lips, or tongue, or respiratory distress) or wheezing in the chest, after taking acetylsalicylic acid or other non-steroidal anti-inflammatory medicines;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have suffered from photoallergic or phototoxic reactions (a particular form of reddening and/or blistering of the skin exposed to sunlight) while taking ketoprofen (a non-steroidal anti-inflammatory drug) or fibrates (drugs used to lower the level of fats in the blood);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a peptic ulcer/ stomach or bowel bleeding or if you have suffered in the past from stomach or bowel bleeding, ulceration or perforation;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have chronic digestive problems (e.g. indigestion, heartburn)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or have suffered in the past from stomach or bowel bleeding or perforation, due to previous use of non-steroidal anti&shy;inflammatory drugs (NSAIDs) used for pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have bowel disease with chronic inflammation (Crohn&rsquo;s disease or ulcerative colitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have serious heart failure, moderate or serious kidney problems or serious liver problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a bleeding disorder or a blood clotting disorder;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are severely dehydrated (have lost a lot of body fluids) due to vomiting, diarrhoea or insufficient intake of fluids;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are in third trimester of pregnancy or breast feeding;</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmaist before using Ketesse:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have suffered in the past from a chronic inflammatory disease of the bowel (ulcerative colitis, Crohn&rsquo;s disease);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or have suffered in the past from the other stomach or bowel problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking other medicines that increase the risk of peptic ulcer or bleeding, e.g. oral steroids, some antidepressants (those of the SSRI type, i.e. selective serotonin reuptake inhibitors), agents that prevent blood clots such as aspirin or anticoagulants such as warfarin. In such cases, consult your doctor before taking Ketesse: he/she may want you to take an additional medicine to protect your stomach (e.g. misoprostol or medicines that block the production of stomach acid);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have heart problems, previous stroke or think that you might be at risk of these conditions (for example if you have high blood pressure, diabetes or high cholesterol or are a smoker) you should discuss your treatment with your doctor or pharmacist; Medicines such as Ketesse may be associated with a small increased risk of heart attack (&ldquo;myocardial infarction&rdquo;) or stroke. Any risk is more likely with high doses and prolonged treatment. Do not exceed the recommended dose or duration of treatment;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are elderly: you may be more likely to suffer from side effects (see section 4). If any of these occur, consult your doctor immediately;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from allergy, or if you have had allergy problems in the past;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have kidney, liver or heart problems (hypertension and/or heart failure) as well as fluid retention, or have suffered from any of these problems in the past;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking diuretics or you suffer from very poor hydration and reduced blood volume due to an excessive loss of fluids (e.g. from excessive urination, diarrhoea or vomiting);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are a woman with fertility problems (Ketesse may impair your fertility, therefore you should not use it if you are planning to become pregnant or you are doing fertility tests);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are in the first or second trimester of pregnancy;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from a disorder in the formation of blood and blood cells;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have systemic lupus erythematosus or mixed connective tissue disease (immune system disorders that affect connective tissue);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have varicella (chickenpox), since exceptionally NSAIDs could worsen the infection;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from asthma combined with chronic rhinitis, chronic sinusitis, and/or nasal polyposis as you have a higher risk of allergy to acetylsalicylic acid and/or NSAIDs than the rest of the population. Administration of this medicine can cause asthma attacks or bronchospasm, particularly in patients allergic to acetylsalicylic acid or NSAIDs.</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Children and adolescents</strong></p><p>Ketesse has not been studied in children and adolescent. Therefore, safety and efficacy have not been established and the product should not be used in children and adolescents.</p><p>&nbsp;</p><p><strong>d.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Other medicines and Ketesse</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. There are some medicines that should not be taken together and others that may need their doses to be altered when taken together. Always inform your doctor, dentist or pharmacist if you are using or receiving any of the following medicines in addition to Ketesse:</p><p>&nbsp;</p><p>Inadvisable combinations:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acetylsalycilic acid, corticosteroids or other anti-inflammatory drugs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warfarin, heparin or other medicines used to prevent blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium, used to treat certain mood disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate (anti-cancer medicine or immunosuppressant), used at high doses of 15 mg/week</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydantoins and phenytoin, used for epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sulfamethoxazole, used for bacterial infections</p><p>&nbsp;</p><p>Combinations requiring precautions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACE inhibitors, diuretics, beta-blockers and angiotensin II antagonists, used for high blood pressure and heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pentoxifylline and oxpentifylline, used to treat chronic venous ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zidovudine, used to treat viral infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aminoglycosides antibiotics, used to treat bacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sulfonylureas (e.g. chlorpropamide and glibenclamide) used for diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate, used at low doses, less than 15 mg/week</p><p>&nbsp;</p><p>Associations to be considered carefully:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quinolone antibiotics (e.g. ciprofloxacin, levofloxacin) used for bacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyclosporin or tacrolimus, used to treat immune system diseases and in organ transplant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Streptokinase and other thrombolytic or fibrinolytic medicines, i.e. medicines used to break-up blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probenecid, used in gout</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin, used to treat chronic heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mifepristone, used as an abortifacient (to terminate a pregnancy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antidepressants of the selective serotonin reuptake inhibitors type (SSRIs)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-platelet agents used to reduce platelet aggregation and the formation of blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-blockers, used for high blood pressure and heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tenofovir, deferasirox, pemetrexed</p><p>&nbsp;</p><p>If you have any doubt about taking other medicines with Ketesse, consult your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>e.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Pregnancy, breast-feeding and fertility</strong></p><p>Do not use Ketesse during the final three months of pregnancy or when breast feeding.</p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine, as Ketesse may not be right for you.</p><p>Use of Ketesse should be avoided by women who are planning a pregnancy or are pregnant. Treatment at any time in pregnancy should only take place as directed by a doctor.</p><p>The use of Ketesse is not recommended while attempting to conceive or during investigation of infertility.</p><p>With regard to potential effects on female fertility, see also section 2, &ldquo;Warnings and precautions&rdquo;.</p><p>&nbsp;</p><p><strong>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Driving and using machines</strong></p><p>Ketesse may slightly affect your ability to drive and handle machines, due to the possibility of dizziness or drowsiness as side effects of treatment. If you notice such effects, do not drive or use machines until the symptoms wear off. Ask your doctor for advice.</p><p>&nbsp;</p><p><strong>g.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Ketesse contains ethanol and sodium</strong></p><p>Each ampoule of Ketesse contains 12.,35 vol% ethanol (alcohol), i.e.up to 200mg per dose, equivalent to 5 ml beer or 2.08 ml wine per dose. Harmful for those suffering from alcoholism.</p><p>To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy. This medicinal product contains less than 1 mmol sodium (23mg) per dosage unit, that is to say essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Your doctor will tell you what is the dose of Ketesse that you need, according to the type, severity and duration of your symptoms. The recommended dose is generally 1 ampoule (50 mg) of Ketesse every 8 - 12 hours. If needed, the injection can be repeated after only 6 hours. Do not exceed a total daily dose of 150 mg of Ketesse (3 ampoules) in any case.</p><p>Use the injection treatment only in the acute period (i.e. no longer than two days). Switch to an oral pain killer when possible.</p><p>The elderly with renal dysfunction and patients with kidney or liver problems should not exceed a total daily dose of 50 mg of Ketesse (1 ampoule).</p><p><strong>&nbsp;</strong></p><p><strong>Method of administration:</strong></p><p>Ketesse can be administered either by intramuscular or by intravenous route (technical details for the intravenous injection are given in the section 7).</p><p>&nbsp;</p><p>When Ketesse is given intramuscularly, the solution should be injected immediately after its removal from the coloured ampoule, by slow injection deep into the muscle.</p><p>Only a clear and colourless solution should be used.</p><p><em>Use in children and adolescents</em></p><p>This medicine should not be used in children and adolescents (under age 18).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you use more Ketesse than you should</strong></p><p>If you use too much of this medicine, tell your doctor or pharmacist immediately or go to the emergency department of your nearest hospital. Please remember to take this medicine pack or this leaflet with you.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you forget to use Ketesse</strong></p><p>Do not use a double dose to make up for a forgotten dose. Use the next regular dose when it is due (according to section 3 &ldquo;How to use Ketesse<strong>&rdquo;</strong>).</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Possible side effects are listed below according to how likely they are to occur.</p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Common side effects: may affect up to 1 in 10 people</strong></p><p>Nausea and/or vomiting, injection site pain, injection site reactions, e.g. inflammation, bruising or haemorrhage.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Uncommon side effects: may affect up to 1 in 100 people</strong></p><p>Vomiting blood, low blood pressure, fever, blurred vision, dizziness, sleepiness, sleep disturbances, headache, anaemia, abdominal pain, constipation, digestive problems, diarrhoea, dry mouth, flushing, rash, dermatitis, itching, sweating increased, tiredness, pain, feeling cold.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Rare side effects: may affect up to 1 in 1,000 people</strong></p><p>Peptic ulcer, peptic ulcer haemorrhage or peptic ulcer perforation, high blood pressure, fainting, too-slow breathing, inflammation of a superficial vein due to a blood clot (superficial thrombophlebitis), isolated heart skip (extrasystole), fast heartbeat, peripheral oedema, laryngeal oedema, abnormal sensation, feeling feverish and shivering, ringing in the ears (tinnitus), itchy rash, jaundice, acne, back pain, renal pain, passing water frequently, menstrual disorders, prostate problems, muscle stiffness, joint stiffness, muscle cramp, abnormal liver tests (blood tests), increased blood sugar level (hyperglyceaemia), decreased blood sugar level (hypogliceaemia), increased triglyceride fats concentration in blood (hypertriglyceridaemia), ketone bodies in the urine (ketonuria), proteins in the urine (proteinuria), liver cell injury (hepatitis), acute renal failure.</p><p>&nbsp;</p><p><strong>d.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Very rare: may affect up to 1 in 10,000 people</strong></p><p>Anaphylactic reaction (hypersensitive reaction which may also lead to a collapse), ulceration of the skin, mouth, eyes and genital areas (Stevens Johnson and Lyell&rsquo;s syndromes), facial swelling or swelling of the lips and throat (angioedema), breathlessness due to contraction of the muscles around the airways (bronchospasm), shortness of breath, pancreatitis, skin sensitivity reactions and skin over-sensitivity to light, renal damage, reduced white blood cell count (neutropenia), reduced platelet count (thrombocytopenia).</p><p>&nbsp;</p><p>Tell your doctor immediately if you notice any stomach/bowel side effects at the start of treatment (e.g. stomach pain, heartburn or bleeding), if you have previously suffered from any such side effects due to long-term use of anti-inflammatory drugs, and especially if you are elderly.</p><p>&nbsp;</p><p>Stop using Ketesse as soon as you notice the appearance of a skin rash, or any lesion on the mucous surfaces (e.g. the surface along the inside of the mouth), or any sign of allergy.</p><p>&nbsp;</p><p>During treatment with non-steroidal anti-inflammatory drugs, fluid retention and swelling (especially in the ankles and legs), a raise in blood pressure and heart failure have been reported.</p><p>&nbsp;</p><p>Medicines such as Ketesse may be associated with a small increased risk of heart attack (&ldquo;myocardial infarction&rdquo;) or cerebrovascular accident (stroke).</p><p>&nbsp;</p><p>In patients with systemic lupus erythematosus or mixed connective tissue disease (immune system disorders that affect connective tissue), anti-inflammatory medicines may rarely cause fever, headache and stiffness of the back of the neck.</p><p>&nbsp;</p><p>The most commonly-observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur. Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, worsening of colitis and Crohn&rsquo;s disease have been reported following administration. Less frequently, inflammation of the stomach lining (gastritis) has been observed.</p><p>&nbsp;</p><p>As with other NSAIDs haematological reactions (purpura, aplastic and haemolytic anaemia, and rarely agranulocytosis and medullar hypoplasia) may appear.</p><p>&nbsp;</p><p>Tell your doctor immediately if signs of infection occur or get worse whilst using Ketesse.</p><p>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>not use this medicine after the expiry date which is stated on the carton and on the ampoule. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Keep the ampoule in the outer carton in order to protect it from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice that the solution is not clear and colourless, but shows signs of deterioration (e.g. particles). Ketesse solution for injection/ infusion is for single use only and should be used immediately once opened. Discard any unused quantity of the product (please see &ldquo;disposal&rdquo; subsection below).</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use and how to properly dispose of your used needles and syringes. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>What Ketesse contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is dexketoprofen (as dexketoprofen trometamol ). Each ampoule contains 50 mg of dexketoprofen.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are alcohol (ethanol, see section 2, Enantyum contains ethanol), sodium chloride, sodium hydroxide and water for injections.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                b.     What Ketesse looks like and contents of the pack

Ketesse is a solution for injection/ infusion. It is supplied in packs containing 1, 5, 6, 10, 20, 50 and 100 type I glass coloured ampoules each one with 2 ml of a clear and colourless solution. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong><em>Marketing Authorisation Holder</em></strong></p><p>Menarini International Operations Luxembourg S.A.,</p><p>1 Avenue de La Gare, L-1611 Luxembourg.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Manufacturer:</strong></p><p>A.&nbsp;&nbsp;&nbsp; Menarini Manufacturing Logistics and Services S.r.l.</p><p>via Sette Santi, 3</p><p>50131 Florence</p><p>Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                f.	This leaflet was last revised in 03/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُعد عقار كيتيس مسكنًا للآلام وينتمي إلى مجموعة من الأدوية تُسمى مضادات الالتهاب غير الستيرويدية.</p><p dir="RTL">يُستخدم هذا العقار لعلاج الألم الحاد المعتدل إلى الشَّديد، عندما يكون تناول الأقراص غير مناسب، مثل آلام ما بعد الجراحة، المغص الكُلوي (ألم كلوي شديد) وآلام الجزء السفلي من الظهر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا تستخدم عقار كيتيس في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه ديكسكيتوبروفين أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء )المدرجة في قسم:6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه حمض أسيتيل الساليسيليك أو تجاه مضادات الالتهاب غير الستيرويدية الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض الربو أو قد عانيت من نوبات الربو، أو التهاب الأنف التحسسي الحاد (التهاب بطانة الأنف لفترة قصيرة)، أو السَّلَئِل الأَنْفِيَّة (ظهور تكتل داخل الأنف بسبب الحساسية)، أو أرتكاريا (طفح جلدي)، أو وذمة وعائية (تورم الوجه أو العينين أو الشفتين أو اللسان، أو ضيق التَّنفس) أو أزيز بالصدر بعد تناوُل حمض أسيتيل الساليسيليك أو غيره من مضادات الالتهاب غير السترويدية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من تفاعلات حساسية تجاه الضوء أو تفاعلات سمية ضوئية (شكل خاص من احمرار الجلد و/ أو النفطات الجلدية عند التعرض لأشعة الشمس) أثناء تناوُل كيتوبروفين (أحد مضادات الالتهاب غير الستيرويدية) أو الفيبرات (أدوية تُستخدم لخفض مستوى الدهون بالدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قرحة هضمية/ نزيف بالمعدة أو بالأمعاء أو إذا كنت قد عانيت في الماضي من انثقاب أو تقرح أو نزيف بالمعدة أو بالأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل هضمية مزمنة (على سبيل المثال: عسر الهضم، الحموضة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت في الماضي من نزيف أو انثقاب بالمعدة أو بالأمعاء، بسبب الاستخدام السابق لمضادات الالتهاب غير الستيرويدية، التي تستخدم لعلاج الألم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض بالأمعاء مصحوب بالتهاب مزمن (مرض كرون أو التهاب القولون التقرُّحي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل خطير بالقلب، مشاكل معتدلة أو خطيرة بالكلى أو مشاكل خطيرة بالكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب نزفي أو اضطراب بتجلط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بجفاف شديد (فقدت كمية كبيرة من سوائل الجسم) بسبب القيء، أو ا إِ لسْهال أو عدم تناوُل السوائل بكمية كافية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ في الثلث الأخير من الحمل أو كنتِ مرضعًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ب. تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل استخدام عقار كيتيس:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت في الماضي من مرض التهابي مزمن بالأمعاء (التهاب القولون التَّقرحي، مرض كرون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو قد عانيت في الماضي من مشاكل أخرى بالمعدة أو الأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى تزيد من خطر الإصابة بقرحة أو نزيف بالمعدة، مثل: الستيرويدات التي يتم تناولها عن طريق الفم، أو بعض مضادات الاكتئاب (من فئة مثبطات إعادة امتصاص السيروتونين الانتقائية)، أو الأدوية التي تحول دون تكوُّن الجلطات الدَّموية مثل:الأسبرين أو مضادات التَّجلط مثل: وارفارين. في مثل هذه الحالات، يُرجى استشارة طبيبك/ طبيبتك قبل تلقي عقار كيتيس؛ فقد يود/ تود منك تناوُل دواء إضافي لحماية معدتك (على سبيل المثال: ميزوبروستول أو الأدوية التي تحول دون إفراز الحمض المعدي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالقلب، أو سكتة دماغية سابقة، أو تعتقد بأنك قد تكون معرضًا لخطر الإصابة بهذه الحالات (على سبيل المثال: إذا كنت تُعاني من ارتفاع ضغط الدَّم، أو مرض السُّكَّريِ أو ارتفاع الكوليسترول أو إذا كنت مدخنًا)، يجب عليك مناقشة علاجك مع طبيبك أو الصيدلي الخاص بك؛ فقد يكون تناوُل أدوية مثل عقار كيتيس مصحوب بزيادة ضئيلة في خطر الإصابة بنوبة قلبية (&quot;احتشاء عضلة القلب&quot;) أو سكتة دماغية. من المرجح حدوث أي من هذه المخاطر مع الجرعات المرتفعة والعلاج المطول. لا تتجاوز الجرعة المُوصى بها أو مدة العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت من كبار السن: فقد تكون أكثر عُرضة للإصابة بالآثار الجانبية (انظر قسم: 4). إذا حدث لك أي من هذه الآثار الجانبية، استشر طبيبك فورًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية، أو إذا كنت قد أصبت بمشاكل متعلقة بالحساسية في الماضي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكلى، أو الكبد أو القلب (ارتفاع ضغط الدَّم و/ أو فشل القلب( وكذلك احتباس السوائل، أو قد عانيت في الماضي من أي من هذه المشاكل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول مُدِرات البول أو تعاني من ترطيب ضعيف جدًّا وانخفاض حجم الدَّم نتيجة الفقدان الشديد للسوائل (على سبيل المثال: نتيجة فرط التَّبول أو ا إِ لسْهال أو القيء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ سيدة تعاني من مشاكل بالخصوبة )قد يضعف عقار كيتيس الخصوبة لديكِ؛ لذلك يجب عليكِ تجنب استخدامه إذا كنتِ تنوين الحمل أو إذا كنتِ تقومين بإجراء اختبارات الخصوبة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ في الثلث الأول أو الثاني من الحمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب في تكون الدَّم وخلايا الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الذئبة الحمامية الجهازية أو مرض مختلط بالأنسجة الضامة (اضطرابات الجهاز المناعي التي تُؤثر على الأنسجة الضامة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحماق (الجدري المائي)؛ إذ من الممكن أن تُؤدي مضادات الالتهاب غير الستيرويدية بشكل استثنائي إلى تفاقم العدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض الربو المصحوب بالتهاب الأنف المزمن، أو الْتِهاب الجُيوب الأنفية المزمن و/ أو مرض السَّلائل الأنفية؛ إذ يكون لديك خطر أكبر للإصابة بحساسية تجاه حمض أسيتيل الساليسيليك و/ أو مضادات الالتهاب غير الستيرويدية عن بقية شريحة المرضى.</p><p dir="RTL">من الممكن أن يُسبب إعطاء هذا الدَّواء الإصابة بنوبات الربو أو التَّشنج القصبي، لا سيما في المرضى ممن لديهم حساسية تجاه حمض أسيتيل الساليسيليك أو مضادات الالتهاب غير الستيرويدية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ج. الأطفال والمراهقون</strong></p><p dir="RTL">لم تتم دراسة استخدام عقار كيتيس في الأطفال والمراهقين. لذلك، لم يتم التَّأكد من أمان وفعَّالية العقار ويجب تجنب استخدام المنتج في الأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د. تناوُل أدوية أخرى مع عقار كيتيس</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية. هناك بعض الأدوية التي يجب تجنُّب تناوُلها بالتَّزامن وأدوية أخرى قد تتطلب تغيير جرعاتها عند تناوُلها بالتَّزامن.</p><p dir="RTL">دائمًا أبلغ طبيبك أو طبيب الأسنان أو الصيدلي الخاص بك إذا كنت تستخدم أو تتلقى أيًّا من الأدوية التَّالية إلى جانب عقار كيتيس: .</p><p dir="RTL">&nbsp;</p><p dir="RTL">التركيبات التي لا ينصح باستخدامها:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض أسيتيل الساليسيليك أو الكورتيكوستيرويدات أو الأدوية الأخرى المضادة للالتهاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوارفارين أو الهيبارين أو غيرهما من الأدوية التي تُستخدم لمنع تجلط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم الذي يُستخدم في علاج بعض اضطرابات الحالة المزاجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميثوتريكسات (دواء مضاد للسرطان أو كابت للمناعة)، يُستخدم بجرعات مرتفعة تبلغ 15 مجم/ أسبوع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيدانتوين وفينيتوين ، يُستخدمان لعلاج الصرع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;سلفاميثوكسازول، يُستخدم لعلاج العدوى البكتيرية</p><p dir="RTL">&nbsp;</p><p dir="RTL">التركيبات التي تتطلب اتخاذ احتياطات:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات الإنزيم المُحوِّل للأنجيوتنسين، مُدِرات البول، حاصرات بيتا ومناهضات أنجيوتنسين 2، يتم استخدامها لعلاج ارتفاع ضغط الدَّم ومشاكل القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بنتوكسيفيلين وأوكسبنتيفيللين المستخدمان لعلاج القرح الوريديةالمزمنة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيدوفودين، يُستخدم لعلاج العدوى الفيروسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية من فئة الأمينوجليكوزيدات المستخدمة في علاج العدوى البكتيرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلفونيل يوريا (على سبيل المثال: كلُورْبرُوباميد وجليبنكلاميد) المستخدمان لعلاج مرض السُّكَّريِ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسات، يُستخدم بجرعات منخفضة، أقل من 15 مجم/ أسبوع</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأدوية المصاحبة التي يجب النَّظر فيها بعناية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية من فئة الكينولون (على سبيل المثال: سيبروفلوكساسين، ليفوفلوكساسين) المستخدمة لعلاج العدوى البكتيرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين أو تاكروليموس، المستخدمان لعلاج أمراض الجهاز المناعي وفي حالة زراعة الأعضاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستربتوكيناز والأدوية الأخرى الحالَّة للتَّخثر أو الأدوية الحالّة للفِيبْرين على سبيل المثال: الأدوية التي تُستخدم لإذابة الجلطات الدَّموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروبنيسيد، يُستخدم لعلاج مرض النقرس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسِين، يُستخدم لعلاج فشل القلب المزمن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميفيبريستون، يُستخدم في هيئة عامل مجهض (لإنهاء الحمل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب من فئة مثبطات إعادة امتصاص السيروتونين الانتقائية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للصفائح الدَّموية التي تُستخدم لخفض تكدس الصَّفائح الدَّموية و تكوين الجلطات الدَّموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا، المستخدمة لعلاج ارتفاع ضغط الدَّم ومشاكل القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تينوفوفير، ديفيراسيروكس، بيميتريكسيد</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي شك حول تناوُل أدوية أخرى مع عقار كيتيس، فاستشر طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ه. الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">لا تستخدمي عقار كيتيس خلال الأشهر الثلاثة الأخيرة من الحمل أو أثناء الرضاعة الطبيعية.</p><p dir="RTL">إذا كنتِ حاملً أو تعتقدين أنك قد تكونين حاملً أو تخططين لذلك، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تلقي هذا الدَّواء؛ إذ قد لا يكون عقار كيتيس مناسبًا لكِ.</p><p dir="RTL">يجب تجنُّب استخدام عقار كيتيس من قِبل السيدات اللاتي تعتزمن الحمل أو السيدات الحوامل. يجب أن يتم العلاج في أي وقت أثناء الحمل فقط وفقًا لتوجيهات الطبيب.</p><p dir="RTL">لا يوصى باستخدام عقار كيتيس أثناء محاولة الحمل أو أثناء إجراء فحوصات الخصوبة.</p><p dir="RTL">فيما يتعلق بالتَّأثيرات المُحتملة على خصوبة الإناث، انظري أيضًا قسم: 2، &ldquo;تحذيرات واحتياطات&rdquo;.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>و. القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يُؤثر عقار كيتيس بشكل طفيف في قدرتك على القيادة والتَّعامل مع الآلات؛ نظرًا لاحتمالية حدوث دوخة أو نعاس باعتبارها آثارًا جانبية للعلاج. إذا لاحظت حدوث هذه الآثار، فتجنب القيادة أو استخدام الآلات حتى زوال الأعراض. يُرجى استشارة طبيبك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ز. يحتوي عقار كيتيس على الإيثانول والصوديوم</strong></p><p dir="RTL">يحتوي كل أمبول من عقار كيتيس على الإيثانول (أحد أنواع الكحوليات) بنسبة 12.35 ٪ من حجمه أي ما يصل إلى 200 مجم لكل جرعة، بما يُعادل 5 مللي لتر من الجعة أو 2.08 مللي لتر من النبيذ لكل جرعة.</p><p dir="RTL">ضار بالنسبة للأشخاص الذين يعانون من إدمان الكحوليات.</p><p dir="RTL">يُؤخذ ذلك بعين الاعتبار عند إعطائه للسيدات الحوامل أو اللاتي يمارسن الرضاعة الطبيعيَّة والأطفال والفئات المعرضة لخطر كبير مثل: المرضى المُصابين بمرض بالكبد أو بالصرع.</p><p dir="RTL">يحتوي هذا المنتج الدَّوائي على أقل من 1 مللي مول من الصوديوم (23 مجم) لكل وحدة للجرعة، أي أنه &ldquo;خال من الصوديوم&rdquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. راجع طبيبك أو الصيدلي الخاص بك إذا لم تأكدًا من كيفيةالاستخدام.</p><p dir="RTL">سيخبرك طبيبك بالجرعة التي تحتاج إليها من عقار كيتيس وفقًا لنوع الألم وشدته ومدة إصابتك بالأعراض. تبلغ الجرعة المُوصى بها بصفة عامة أمبولً واحدًا ( 50 مجم) من عقار كيتيس كل 8 &ndash; 12 ساعة. إذا لزم الأمر، يمكن إعادة حقن العقار بعد 6 ساعات فحسب. يجب عليك ألا تتجاوز إجمالي الجرعة اليومية من عقار كيتيس والذي يبلغ 150 مجم ( 3 . ت</p><p dir="RTL">أمبولات) في أي حال من الأحوال.</p><p dir="RTL">لا تستخدم العلاج بالحُقْن إلا خلال فترة الألم الحاد (أي ما لا يزيد عن يومين). انتقل إلى استخدام أحد مسكنات الألم التي يتم تناولها عن طريق الفم متى أمكن ذلك.</p><p dir="RTL">ينبغي على كبار السن المُصابين بقصور في وظائف الكُلى والمرضى الذين يعانون من مشاكل بالكُلى أو الكبد ألا يتجاوزوا إجمالي الجرعة اليومية من عقار كيتيس والتي تبلغ 50 مجم (أمبولً واحدًا).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>طريقة الإعطاء</strong><strong>:</strong></p><p dir="RTL">يمكن إعطاء عقار كيتيس إما عن طريق العضل أو عن طريق الوريد (تتوافر التفاصيل التقنية فيما يخص الحقن عن طريق الوريد في قسم:7).</p><p dir="RTL">عند إعطاء عقار كيتيس عن طريق العضل، ينبغي حقن المحلول فور إفراغه من الأمبول المُلون، من خلال الحقن العميق البطيء داخل العضلة.</p><p dir="RTL">ينبغي عدم استخدام المحلول ما لم يكن صافيًا وعديم اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الاستخدام في الأطفال والمراهقين</p><p dir="RTL">يجب ألاَّ يُستَخدَم هذا الدَّواء في الأطفال والمراهقين (الذين تقل أعمارهم عن 18 عامًا).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أ. إذا استخدمت كمية أكثر مما يجب من عقار كيتيس</strong></p><p dir="RTL">إذا كمية كبيرة جدًّا من هذا الدَّواء، فأخبر طبيبك أو الصيدلي الخاص بك فورًا، أو اذهب إلى قسم الطَّوارئ بأقرب استخدمت مستشفى لك.</p><p dir="RTL">رجاءً تذكّر أخذ عبوة هذا الدَّواء أو هذه النشرة معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. إذا أغفلت استخدام عقار كيتيس</strong></p><p dir="RTL">لا تستخدم جرعة مضاعفة لتعويض جرعة أغفلتها. استخدم الجرعة التَّالية المعتادة عندما يحين موعدها (وفقًا للقسم: 3 &ldquo;كيف استخدام عقار كيتيس&rdquo;).</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">تم إدراج الآثار الجانبية المحتملة أدناه وفقًا لمدى احتمالية حدوثها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ. الآثار الجانبية الشائعة: قد تؤثر على ما يصل إلى شخص واحد من</strong><strong> </strong><strong>بين كل 10 أشخاص</strong></p><p dir="RTL">غثيان و/ أو قيء، ألم بموضع الحقن، تفاعلات بموضع الحقن، على سبيل المثال: التهاب، كدمات أو نزيف.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ب. الآثار الجانبيَّة غير الشَّائعة: قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص</strong></p><p dir="RTL">تقيؤ مدمم، انخفاض ضغط الدَّم، حُمّى، عدم وضوح الرؤية، دوخة، نعاس، اضطرابات بالنوم، صداع، فقر الدَّم، ألم بالبطن، إمساك، مشاكل بالهضم، إسهال، جُفاف الفَم، احمرار الجلد، طفح جلدي، التهاب جلدي، حكة، زيادة التعرق، تعب، ألم، الشعور بالبرد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ج. الآثار الجانبية النَّادرة: قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص</strong></p><p dir="RTL">قرحة هضمية، نزيف أو انثقاب ناجم عن القرحة الهضمية، ارتفاع ضغط الدَّم، إغماء، التَّنفس بشكل بطيء جدًّا، التهاب أحد الأوردة السطحية نتيجة تجلط الدَّم (التهاب الوريد الخثاري السطحي)، تخطي ضربة مفردة من ضربات القلب ( انْقِباضَة خارجِية)، ضربات قلب سريعة، وذمة طرفية، وذمة بالحنجرة، إحساس غير طبيعي، شعور بحُمى وارتعاش، طنين بالأذن، حكة، طفح جلدي، يرقان، حب الشباب، ألم بالظهر، ألم كُلوي، التبول بشكل متكرر، اضطرابات بالحيض، مشاكل بالبروستاتا، تصلب العضلات، تصلب المفاصل، تقلصات عضلية، نتائج غير طبيعية باختبارات وظائف الكبد (اختبارات الدَّم) ، زيادة مستوى السكر بالدَّم (فرط سكر الدَّم)، انخفاض مستوى السكر بالدَّم (نقص السكر بالدَّم)، زيادة تركيزات الدهون الثلاثية بالدَّم (فرط الدهون الثلاثية بالدَّم)، وجود أجسام كيتونية بالبول (بيلة كيتونية)، وجود بروتينات بالبول (بيلة بروتينية)، إصابة خلايا الكبد (التهاب الكبد)، فشل كُلوي حاد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>د. نادرة جدًّا: قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000شخص</strong></p><p dir="RTL">تفاعل تَأقِيّ (تفاعل فرط حساسية قد يُؤدي أيضًا إلى هبوط)، تقرح الجلد، الفم، العينين، مناطق الأعضاء التناسلية( متلازمة ستيفنز جونسون ومتلازمة لايل)، تورم الوجه، أو تورم الشفتين والحلق (وذمة وعائية)، عسر التَّنَفُّس بسبب تقلص العضلات حول الشُّعب الهوائية (التشنج القصبي)، ضيق التنفس، التهاب البنكرياس، تفاعلات حساسية بالجلد وحساسية مفرطة بالجلد تجاه الضوء، تلف بالكُلى، انخفاض تعداد خلايا الدَّم البيضاء (قلة خلايا العَدِلات)، انخفاض تعداد الصفائح الدَّموية (نقص الصَّفائح الدَّموية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك فورًا إذا لاحظت حدوث أية آثار جانبية بالمعدة/الأمعاء عند بدء العلاج (على سبيل المثال: ألم بالمعدة، أو حموضة أو نزيف)، إذا كنت قد عانيت سابقًا من أيّ من هذه الآثار الجانبية بسبب الاستخدام طويل الأمد للأدوية المضادة للالتهاب، لا سيما إذا كنت من المرضى من كبار السن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توقف عن استخدام عقار كيتيس بمجرد أن تلاحظ ظهور طفح جلدي، أو التَّعرض لأي إصابة على أسطح الأنسجة المخاطية (على سبيل المثال: على طول السطح داخل الفم) أو الإصابة بأي علامة من علامات الحساسية.</p><p dir="RTL">أثناء العلاج بمضادات الالتهاب غير الستيرويدية، تم الإبلاغ عن حدوث احتباس للسوائل وتورم (لا سيما في الكاحلين والساقين)، وارتفاع ضغط الدَّم وفشل القلب.</p><p dir="RTL">قد يصاحب استخدام أدوية مثل عقار كيتيس زيادة ضئيلة في خطر الإصابة بالنوبة القلبية (&ldquo;احتشاء عضلة القلب&rdquo;) أو الإصابة بحادثة وعائية دماغية (السكتة الدِّماغية).</p><p dir="RTL">في المرضى الذين يعانون من الذئبة الحمامية الجهازية أو مرض مختلط بالأنسجة الضَّامة (اضطرابات الجهاز المناعي التي تُؤثر على الأنسجة الضَّامة)، نادرًا ما ت تسبب الأدوية المضادة للالتهاب في الإصابة بالحمى، والصُّداع وتصلب الظهر والرقبة.</p><p dir="RTL">تكون الأحداث العكسية الأكثر شيوعًا التي تمت ملاحظتها متعلقة بالجهاز الهضمي بطبيعتها. قد تحدث قرح هضمية، انثقاب أو نزيف بالجهاز الهضمي، وقد تؤدي إلى الوفاة في بعض الأحيان، خاصة في كبار السن. تم الإبلاغ عن التَّعرض لغثيان، قيء، إسهال، انتفاخ البطن بالغازات، إمساك، عُسْر الهَضْم، ألم بالبطن، تغوط مدمم، قيء دموي، التهاب الفم التَّقرحي، تفاقم التهاب القولون ومرض كرون عقب تلقي العقار. تمت ملاحظة حدوث التهاب ببطانة المعدة (التهاب المعدة) بشكل أقل تكرارًا.</p><p dir="RTL">كما هو الحال مع مضادات الالتهاب غير الستيرويدية الأخرى، قد تظهر تفاعلات مرتبطة بالدَّم (الفرفرية، فقر الدَّم غير التنسجي والانحلالي وبشكل نادر ندرة خلايا المحببات ونقص التنسُّج النخاعي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك فورًا إذا ظهرت لديك علامات تُشير إلى الإصابة بعدوى أو إذا تفاقمت أثناء استخدام عقار كيتيس.</p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك. بما في ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.</p><p dir="RTL">بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية وعلى الأمبول. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بالأمبول داخل العبوة الكرتونية الخارجية لحمايته من الضوء.</p><p dir="RTL">لا تستخدم هذا الدَّواء إذا لاحظت أنَّ المحلول غير صافٍ وعديم اللون وتبدو عليه أية علامات تلف (على سبيل المثال: به جسيمات). عقار كيتيس محلول للحقن/ للتسريب مُعدٌّ للاستخدام مرة واحدة فقط وينبغي استخدامه فورًا بمجرد فتحه. قم بالتَّخلص من أي كمية غير مُستخدمة من المنتج (يُرجى الاطلاع على القسم الفرعي &ldquo;التَّخلص من المنتج&rdquo; أدناه).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها وكيفية التَّخلص من الإبر و السرنجات المستخدمة الخاصة بك بشكل صحيح. ستُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ. محتويات عقار كيتيس</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ديكسكيتوبروفين (في هيئة ديكسكيتوبروفين تروميتامول). يحتوي كل أمبول على 50 مجم من ديكسكيتوبروفين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: الكحول )الإيثانول، انظر قسم: 2 يحتوي إينانتيوم على الإيثانول(، كلوريد الصوديوم، هيدروكسيد الصوديوم وماء للحقن.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار كيتيس هو محلول للحقن/ للتسريب. يتوافر في عبوات بها أمبول واحد 50،20،10،6،5 و 100 أمبولات ملونة مصنوعة من الزجاج من النوع 1، يحتوي كل منها على محلول صافٍ وعديم اللون بحجم 2 مللي لتر. قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ج. مالك حق التَّسويق</strong></p><p dir="RTL">ميناريني إنترناشونال أوبيريشنز لوكسمبرج، شركة مساهمة،</p><p dir="RTL">1 شارع دي لا جار ،1611،لوكسمبرج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>د. جهة التَّصنيع</strong><strong>:</strong></p><p dir="RTL">أيه. ميناريني لخدمات التَّصنيع واللوجستية شركة ذات مسؤولية محدودة.</p><p dir="RTL">فيا سيت سانتي، 3</p><p dir="RTL">50131 فلورنسا</p><p dir="RTL">إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت آخر مراجعة لهذه النَّشرة في 03/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ketesse 50 mg/2ml solution for injection/ infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ampoule of 2 ml contains: dexketoprofen 50 mg (as dexketoprofen trometamol). Each ml of solution for injection/ infusion contains dexketoprofen 25 mg (as dexketoprofen trometamol)

Excipients with known effects: 100 mg ethanol (96 per cent) and 4.0 mg sodium chloride. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection/ infusion.
Clear and colourless solution. pH (7.0-8.0)
Osmolarity (270-328 mOsmol/l)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptomatic treatment of acute pain of moderate to severe intensity, when oral administration is not appropriate such as post-operative pain, renal colic and low back pain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Adults</em></p><p>The recommended dose is 50 mg every 8 - 12 hours. If necessary, the administration can be repeated 6 hours apart. The total daily dose should not exceed 150 mg.</p><p>Ketesse solution for injection/ infusion is intended for short term use and the treatment must be limited to the acute symptomatic period (no more than two days). Patients should be switched to an oral analgesic treatment when possible.</p><p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4).</p><p>&nbsp;</p><p>In case of moderate to severe postoperative pain, Ketesse solution for injection/ infusion can be used in combination with opioid analgesics, if indicated, at the same recommended doses in adults (see section 5.1).</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>No dosage adjustment is generally necessary in older patients. However because of the physiological decline in renal function in elderly patients a lower dose is recommended in case of mild renal function impairment: 50 mg total daily dose (see section 4.4).</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>The dosage should be reduced to 50 mg total daily dose in patients with mild to moderate (Child-Pugh score 5 - 9) hepatic impairment and hepatic function should be closely monitored (see section 4.4). Ketesse solution for injection/ infusion should not be used in patients with severe hepatic dysfunction (Child-Pugh score 10 - 15) (see section 4.3).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>The dosage should be reduced to 50 mg total daily dose in patients with mildly impaired renal function (creatinine clearance 60 - 89 ml / min) (see section 4.4). Ketesse solution for injection/ infusion should not be used in patients with moderate to severe renal dysfunction (creatinine clearance &lt;59 ml / min) (see section 4.3).</p><p><em>&nbsp;</em></p><p><em>Pediatric population</em></p><p>Ketesse has not been studied in children and adolescent. Therefore the safety and efficacy in children and adolescents have not been established and the product should not be used in children and adolescent.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>Ketesse solution for injection/ infusion can be administered either by intramuscular or by intravenous route:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intramuscular use: the content of one ampoule (2 ml) of Ketesse solution for injection/ infusion should be administered by slow injection deep into the muscle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intravenous use:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intravenous infusion: the diluted solution, prepared as described in section 6.6, should be administered as a slow intravenous infusion, lasting 10 to 30 min. The solution must be always protected from natural daylight.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intravenous bolus: if necessary, the content of one ampoule (2 ml) of Ketesse Solution for injection/ infusion can be administered in a slow intravenous bolus over no less than 15 seconds.</p><p><u>&nbsp;</u></p><p><u>Instructions on handling the product:</u></p><p>When Ketesse solution for injection/ infusion is administered intramuscularly or as intravenous bolus, the solution should be injected immediately after its removal from the coloured ampoule (see also sections 6.2 and 6.6).</p><p>For administration as intravenous infusion, the solution should be diluted aseptically and protected from natural daylight (see also section 6.3 and 6.6). For instructions on dilution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ketesse solution for injection/ infusion must not be administered in the following cases:
-	patients with hypersensitivity to the active substance, to any other NSAID, or to any of the excipients listed in section 6.1.
-	patients in whom substances with a similar action (e.g. acetylsalicylic acid and other NSAIDs) precipitate attacks of asthma, bronchospasm, acute rhinitis, or cause nasal polyps, urticaria or angioneurotic oedema.
-	known photoallergic or phototoxic reactions during treatment with ketoprofen or fibrates
-	patients with history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy.
-	patients with active peptic ulcer/gastrointestinal haemorrhage or any history of gastrointestinal bleeding, ulceration or perforation.
-	patients with chronic dyspepsia.
-	patients who have other active bleedings or bleeding disorders.
-	patients with Crohn’s disease or ulcerative colitis.
-	patients with severe heart failure.
-	patients with moderate to severe renal dysfunction (creatinine clearance <59 ml/min).
-	patients with severely impaired hepatic function (Child-Pugh score 10 - 15).
-	patients with haemorrhagic diathesis and other coagulation disorders.
-	patients with severe dehydration (caused by vomiting, diarrhoea or insufficient fluid intake)
-	during the third trimester of pregnancy and lactation period (see section 4.6).

Ketesse solution for injection/ infusion is contraindicated for neuraxial (intrathecal or epidural) administration due to its ethanol content.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Administer with caution in patients with a history of allergic conditions.</p><p>&nbsp;</p><p>The use of Ketesse with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided.</p><p>&nbsp;</p><p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2, and gastrointestinal and cardiovascular risks below).</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Gastrointestinal safety</u></strong></p><p>Gastrointestinal bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at anytime during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events. When gastrointestinal bleeding or ulceration occurs in patients receiving Ketesse, the treatment should be withdrawn.</p><p>The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in the elderly.</p><p>Elderly: the elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2). These patients should commence treatment on the lowest dose available.</p><p>As with all NSAIDs, any history of oesophagitis, gastritis and/or peptic ulcer must be sought in order to ensure their total cure before starting treatment with dexketoprofen trometamol. Patients with gastrointestinal symptoms or history of gastrointestinal disease should be monitored for digestive disturbances, especially gastrointestinal bleeding.</p><p>NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn&rsquo;s disease) as their condition may be exacerbated (see section 4.8). Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose acetylsalicylic acid, or other drugs likely to increase gastrointestinal risk (see below and section 4.5).</p><p>Patients with a history of gastrointestinal toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) particularly in the initial stages of treatment.</p><p>Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as acetylsalicylic acid (see section 4.5).</p><p><u>&nbsp;</u></p><p><u>Renal Safety</u></p><p>Caution should be exercised in patients with impairment of renal functions. In these patients, the use of NSAIDs may result in deterioration of renal function, fluid retention and oedema. Caution is also required in patients receiving diuretic therapy or those who could develop hypovolaemia as there is an increased risk of nephrotoxicity.</p><p>Adequate fluid intake should be ensured during treatment to prevent dehydration and possibly associated increased renal toxicity.</p><p>As with all NSAIDs, it can increase plasma urea nitrogen and creatinine. As with other inhibitors of prostaglandin synthesis, it can be associated with adverse effects on the renal system, which can lead to glomerular nephritis, interstitial nephritis, renal papillary necrosis, nephrotic syndrome and acute renal failure.</p><p>Elderly patients are more likely to be suffering from impaired renal function (see section 4.2).</p><p><u>&nbsp;</u></p><p><u>Liver Safety</u></p><p>Caution should be exercised in patients with impairment of hepatic functions. As with other NSAIDs, it can cause transient small increases in some liver parameters, and also significant increases in SGOT and SGPT. In case of a relevant increase in such parameters, therapy must be discontinued.</p><p>Elderly patients are more likely to be suffering from impaired hepatic function (see section 4.2).</p><p>&nbsp;</p><p><u>Cardiovascular and cerebrovascular safety</u></p><p>Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate heart failure. Special caution should be exercised in patients with a history of cardiac disease, in particular those with previous episodes of heart failure as there is an increased risk of triggering heart failure, since fluid retention and oedema have been reported in association with NSAIDs therapy.</p><p>&nbsp;</p><p>Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude such a risk for dexketoprofen.</p><p>Consequently, patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with dexketoprofen after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).</p><p>&nbsp;</p><p>All non-selective NSAIDs can inhibit platelet aggregation and prolong bleeding time via inhibition of prostaglandin synthesis. The concomitant use of dexketoprofen and prophylactic doses of low molecular weight heparin in the postoperative period has been assessed in controlled clinical trials and no effect on coagulation parameters was observed. Nevertheless, patients who are receiving therapy that interferes with haemostasis, such as warfarin or other coumarins or heparins should be carefully monitored if dexketoprofen is administered (see Section 4.5).</p><p>Elderly patients are more likely to be suffering from impaired cardiovascular function (see section 4.2).</p><p><u>&nbsp;</u></p><p><u>Skin reactions</u></p><p>Serious skin reactions (some of them fatal), including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Ketesse solution for injection/ infusion should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p><u>Other information</u></p><p>Particular caution is required in patients with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; congenital disorder of porphyrin metabolism (e.g. acute intermittent porphyria)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directly after major surgery</p><p>&nbsp;</p><p>If the physician considers long-term dexketoprofen therapy to be necessary, hepatic and renal function and the blood count should be regularly checked.</p><p>&nbsp;</p><p>Severe acute hypersensitivity reactions (anaphylactic shock, for example) have been observed on very rare occasions. Treatment must be discontinued at the first signs of severe hypersensitivity reactions following intake of Ketesse. Depending on the symptoms, any medically required procedures must be initiated by specialist healthcare professionals.</p><p>&nbsp;</p><p>Patients with asthma combined with chronic rhinitis, chronic sinusitis, and/or nasal polyposis have a higher risk of allergy to acetylsalicylic acid and/or NSAIDs than the rest of the population. Administration of this medicinal product can cause asthma attacks or bronchospasm, particularly in subjects allergic to acetylsalicylic acid or NSAIDs (see section 4.3).</p><p>Exceptionally, varicella can be at the origin of serious cutaneous and soft tissues infectious complications. To date, the contributing role of NSAIDs in the worsening of these infections cannot be ruled out. Thus, it is advisable to avoid use of Ketesse in case of varicella.</p><p>&nbsp;</p><p>Ketesse solution for injection/ infusion should be administered with caution to patients suffering from haematopoietic disorders, systemic lupus erythematosus or mixed connective tissue disease.</p><p>&nbsp;</p><p>As other NSAIDs, dexketoprofen can mask the symptoms of infectious diseases. In isolated cases an aggravation of soft tissue infections has been described in temporal connection with the use of NSAIDs. Therefore the patient is advised to consult a physician immediately if signs of a bacterial infection occur or worsen during therapy.</p><p>&nbsp;</p><p>Each ampoule of Ketesse solution for injection/ infusion contains 12.35 vol% ethanol (alcohol), i.e. up to 200 mg per dose, equivalent to 5 ml beer or 2.08 ml wine per dose.</p><p>Harmful for those suffering from alcoholism.</p><p>To be taken into account in pregnant and breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy.</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23mg) per dose, i.e. essentially &ldquo;sodium-free&rdquo;.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>The safe use in children and adolescents has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following interactions apply to non-steroidal antiinflammatory drugs (NSAIDs) in general:</p><p>&nbsp;</p><p>Inadvisable combinations:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other NSAIDs (including cyclooxygenase-2 selectve inhibitors) and high doses of salicylates (&gt; 3 g/day): administration of several NSAIDs together may increase the risk of gastrointestinal ulcers and bleeding, via a synergistic effect.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anticoagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see section 4.4), due to the high plasma protein binding of dexketoprofen and the inhibition of platelet function and damage to the gastroduodenal mucosa. If the combination cannot be avoided, close clinical observation and monitoring of laboratory values should be carried out.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heparins: increased risk of haemorrhage (due to the inhibition of platelet function and damage to the gastroduodenal mucosa). If the combination cannot be avoided, close clinical observation and monitoring of laboratory values should be carried out.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium (described with several NSAIDs): NSAIDs increase blood lithium levels, which may reach toxic values (decreased renal excretion of lithium). This parameter therefore requires monitoring during the initiation, adjustment and withdrawal of treatment with dexketoprofen.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate, used at high doses of 15 mg/week or more: increased haematological toxicity of methotrexate via a decrease in its renal clearance by antiinflammatory agents in general.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydantoines and sulphonamides: the toxic effects of these substances may be increased.</p><p>&nbsp;</p><p>Combinations requiring precautions:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diuretics, ACE inhibitors, antibacterial aminoglycosides and angiotensin II receptor antagonists: Dexketoprofen may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e. g. dehydrated patients or elderly patients with compromised renal function), the coadministration of agents that inhibit cyclo-oxygenase and ACE inhibitors, angiotensin II receptor antagonists or antibacterial aminoglycosides may result in further deterioration of renal function, which is usually reversible. In case of combined prescription of dexketoprofen and a diuretic, it is essential to ensure that the patient is adequately hydrated and to monitor renal function at the start of the treatment (see section 4.4 Special warnings and special precautions for use).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate, used at low doses, less than 15 mg/week: increased haematological toxicity of methotrexate via a decrease in its renal clearance by antiinflammatory agents in general. Weekly monitoring of blood count during the first weeks of the combination. Increased surveillance in the presence of even mildly impaired renal function, as well as in the elderly.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pentoxyfylline: increased risk of bleeding. Intensify clinical monitoring and check bleeding time more often.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Zidovudine: risk of increased red cell line toxicity via action on reticulocytes, with severe anaemia occurring one week after the NSAID is started. Check complete blood count and reticulocyte count one to two weeks after starting treatment with the NSAID.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sulfonylureas: NSAIDs can increase the hypoglycaemic effect of sulfonylureas by displacement from plasma protein binding sites.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Combinations needing to be taken into account:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-blockers: treatment with a NSAID may decrease their antihypertensive effect via inhibition of prostaglandin synthesis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cyclosporin and tacrolimus: nephrotoxicity may be enhanced by NSAIDs via renal prostaglandin mediated effects. During combination therapy, renal function has to be measured.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombolytics: increased risk of bleeding.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probenecid: plasma concentrations of dexketoprofen may be increased; this interaction can be due to an inhibitory mechanism at the site of renal tubular secretion and of glucuronoconjugation and requires adjustment of the dose of dexketoprofen.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac glycosides: NSAIDs may increase plasma glycoside concentration.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mifepristone: There is a theoretical risk that prostaglandin synthetase inhibitors may alter the efficacy of mifepristone. Limited evidence suggests that co-administration of NSAIDs on the day of prostaglandin administration does not adversely influence the effects of mifepristone or the prostaglandin on cervical ripening or uterine contractility and does not reduce the clinical efficacy of medical termination of pregnancy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quinolone Antibiotics: Animal data indicate that high doses of quinolones in combination with NSAIDs can increase the risk of developing convulsions.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tenofovir: concomitant use with NSAID can increase plasma urea nitrogen and creatinine, renal function should be monitored in order to control a potential synergic influence on renal function.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferasirox: concomitant use with NSAIDs can increase the risk of gastrointestinal toxicity. Close clinical monitoring is required when deferasirox is combined with these substances.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pemetrexed: concomitant use with NSAIDs may decrease pemetrexed elimination, therefore caution should be made when administering higher doses of NSAIDs. In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs doses should be avoided for 2 days before and 2 days following pemetrexed administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ketesse solution for injection/ infusion is contraindicated during third trimester of pregnancy</p><p>and lactation (see section 4.3).</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies raise concern about an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. Nevertheless, animal studies with dexketoprofen haven&rsquo;t shown reproductive toxicity (see section 5.3). During the first and second trimester of pregnancy, dexketoprofen should not be given unless clearly necessary. If dexketoprofen is used by a women attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.</p><p>&nbsp;</p><p>During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to:</p><p>-cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);</p><p>-renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;</p><p>&nbsp;</p><p>the mother and the neonate, at the end of pregnancy, to:</p><p>-possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses;</p><p>-inhibition of uterine contractions resulting in delayed or prolonged labour.</p><p><u>&nbsp;</u></p><p><u>Breastfeeding</u></p><p>It is not known whether dexketoprofen is excreted in human milk. Ketesse is contraindicated during breast-feeding (see section 4.3).</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>As with other NSAIDs, the use of Ketesse may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of dexketoprofen should be considered.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ketesse solution for injection/ infusion may cause undesirable effects such as dizziness, visual disturbances or drowsiness. The ability to react and the ability to take part actively in road traffic and to operate machines may be impaired in these cases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse events reported as at least possibly related with dexketoprofen trometamol in clinical trials, as well as the adverse reaction reported after the marketing of Ketesse 50mg/2ml solution for injection/ infusion are tabulated below, classified by system organ class and ordered by frequency:</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td style="vertical-align:top"><p><strong>SYSTEM</strong></p><p><strong>ORGAN</strong></p><p><strong>CLASS</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&gt;1/100 to &lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon </strong></p><p><strong>(&gt;1/1000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&gt;1/10000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt;1/10000)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Neutropenia,</p><p>thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune</strong></p><p><strong>system</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>----</p></td><td style="vertical-align:top"><p>Laryngeal oedema</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, including anaphylactic shock</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Hyperglyceaemia, hypoglyceaemia, hypertriglyceridaemia, anorexia</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous</strong></p><p><strong>system</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Headache, dizziness, Somnolence</p></td><td style="vertical-align:top"><p>Paraesthesia,</p><p>syncope</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>Blurred vision</p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>&mdash;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and</strong></p><p><strong>labyrinth</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>Extrasystole,</p><p>tachycardia</p></td><td style="vertical-align:top"><p>&mdash;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Hypotension,</p><p>flushing</p></td><td style="vertical-align:top"><p>Hypertension,</p><p>thrombophlebitis</p><p>superficial</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Bradypnoea</p></td><td style="vertical-align:top"><p>Bronchospasm, dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea,</p><p>vomiting</p></td><td style="vertical-align:top"><p>Abdominal pain, dyspepsia, diarrhoea,constipation, haematemesis, dry mouth</p></td><td style="vertical-align:top"><p>Peptic ulcer, peptic ulcer haemorrhage or peptic ulcer perforation (see section 4.4)</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Hepatocellular injury</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>SYSTEM</strong></p><p><strong>ORGAN</strong></p><p><strong>CLASS</strong></p></td><td style="vertical-align:top"><p><strong>Common </strong></p><p><strong>(&gt;1/100 to &lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&gt;1/1000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&gt;1/10000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Very rare (&lt;1/10000)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Dermatitis, pruritus, rash, sweating increased</p></td><td style="vertical-align:top"><p>Urticaria, acne</p></td><td style="vertical-align:top"><p>Stevens Johnson syndrome, toxic epidermal necrolysis (Lyell&#39;s syndrome), angioedema, facial oedema, photosensitivity reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Muscle stiffness, joint stiffness, muscle cramp, back pain</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and</strong></p><p><strong>urinary</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Acute renal failure, Polyuria, renal pain, ketonuria, proteinuria</p></td><td style="vertical-align:top"><p>Nephritis or nephrotic syndrome</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>---</p></td><td style="vertical-align:top"><p>Menstrual disorder, prostatic disorder</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Injection site pain, injection site reaction, including</p><p>inflammation, bruising or haemorrhage</p></td><td style="vertical-align:top"><p>Pyrexia, fatigue, pain, feeling cold</p></td><td style="vertical-align:top"><p>Rigors, peripheral oedema</p></td><td style="vertical-align:top"><p>---</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>&mdash;</p></td><td style="vertical-align:top"><p>Liver function test abnormal</p></td><td style="vertical-align:top"><p>&mdash;</p></td></tr></tbody></table><p>&nbsp;</p><p>The most commonly-observed adverse events are gastrointestinal in nature. Peptic ulcers, perforation or gastrointestinal bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn&rsquo;s disease (See section 4.4 Special warnings and precautions for use) have been reported following administration. Less frequently, gastritis has been observed. Oedema, hypertension, and cardiac failure, have been reported in association with NSAID treatment.</p><p>As with other NSAIDs the following undesirable effects may appear: aseptic meningitis, which might predominantly occur in patients with systemic lupus erythematosus or mixed connective tissue disease; and haematological reactions (purpura, aplastic and haemolytic anaemia, rarely agranulocytosis and medullar hypoplasia).</p><p>&nbsp;</p><p>Bullous reactions including Stevens Johnson Syndrome and Toxic Epidermal Necrolysis (very rare).</p><p>Clinical trial and epidemiological data suggest that use of some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>To report any side effect(s)</u></p><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia:</u></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp;&nbsp; Toll free phone: 8002490000</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p><u>&nbsp;</u></p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States:</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The symptomatology following overdose is not known. Similar medicinal products have produced gastrointestinal (vomiting, anorexia, abdominal pain) and neurological (somnolence, vertigo, disorientation, headache) disorders.</p><p>In case of accidental or excessive intake or administration, immediately institute symptomatic therapy according to the patient&rsquo;s clinical condition.</p><p>Dexketoprofen trometamol may be removed by dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: propionic acid derivatives ATC code: M01AE17 Dexketoprofen trometamol is the tromethamine salt of S-(+)-2-(3-benzoylphenyl) propionic acid, an analgesic, antiinflammatory and antipyretic medicinal product, which belongs to the non-steroidal anti-inflammatory group of drugs (M01AE).</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p>The mechanism of action of non-steroidal antiinflammatory medicinal products is related to the reduction of prostaglandin synthesis by the inhibition of cyclooxygenase pathway.</p><p>Specifically, there is an inhibition of the transformation of arachidonic acid into cyclic endoperoxides, PGG2 and PGH2, which produce prostaglandins PGE1, PGE2, PGF2a and PGD2 and also prostacyclin PGI2 and tromboxanes (TxA2 and TxB2). Furthermore, the inhibition of the synthesis of prostaglandins could affect other inflammation mediators such as kinins, causing an indirect action which would be additional to the direct action.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>Dexketoprofen has been demonstrated to be an inhibitor of COX-1 and COX-2 activities in experimental animals and humans.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p>Clinical studies performed on several pain models demonstrated effective analgesic activity of dexketoprofen.</p><p>The analgesic efficacy of intramuscular and intravenous dexketoprofen in the management of moderate to severe pain was investigated in several surgical pain models (orthopaedic and gynaecologic/abdominal surgery) as well as in musculo-skeletal pain (acute low back pain model) and renal colic.</p><p>&nbsp;</p><p>In the studies performed, the onset of analgesic effect was rapid, and within the first 45 minutes the peak analgesic effect occurred. Duration of analgesic effect after the administration of 50 mg of dexketoprofen is usually 8 hours.</p><p>&nbsp;</p><p>Clinical studies in postoperative pain management have demonstrated that Ketesse solution for injection/ infusion when used in combination with opioids significantly reduced opioid consumption. In the post-operative pain studies where patients received morphine by a patient controlled analgesia device, patients treated with dexketoprofen required significantly less morphine (between 30 - 45% less) than patients in the placebo group.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After intramuscular administration of dexketoprofen trometamol to humans, the peak concentrations are reached at 20 minutes (range 10 to 45 min). For 25 to 50 mg single doses thearea under the curve has been shown to be dose proportional after both intramuscular and intravenous administration.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>As with other medicinal products with a high plasma protein binding (99%), the volume of distribution has a mean value below 0.25 l/kg. The distribution half-life was approximately 0.35 hours and the elimination half-life ranged between 1 - 2.7 hours.</p><p>In multiple-dose pharmacokinetic studies, it was observed that Cmax and AUC after the last intramuscular or intravenous administration were not different from that obtained following a single dose, indicating that no drug accumulation occurs.</p><p><u>&nbsp;</u></p><p><u>Biotransformation and elimination</u></p><p>After administration of dexketoprofen trometamol only the S-(+) enantiomer is obtained in urine, demonstrating that no conversion to the R-(-) enantiomer occurs in humans The main elimination route for dexketoprofen is glucuronide conjugation followed by renal excretion.</p><p><u>&nbsp;</u></p><p><u>Elderly</u></p><p>In healthy elderly subjects (65 years and older), exposure was significantly higher than in young volunteers after single and repeated oral doses (up to 55%) whereas there was no statistically significant difference in peak concentrations and time to reach peak concentration. The mean elimination half-life was prolonged after single and repeated doses (up to 48%), and the apparent total clearance was reduced.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicityand immunopharmacology. The chronic toxicity studies carried out in mice and monkeys gave a No Observed Adverse Effect Level (NOAEL) at doses 2 fold higher than maximum recommended human dose. In monkey, at higher doses,the main adverse effect observed were blood in faeces, decreased body weight gain and, at the highest dose, erosive gastrointestinal lesions. These effects appeared at doses determining a drug exposure 14-18 fold higher than that at the maximum recommended human dose.</p><p>There are not studies on the carcinogenic potential in animals.</p><p>&nbsp;</p><p>As it has been recognised for the whole pharmacological class of NSAIDs, dexketoprofen may cause changes of embryo-foetal survival in animal models, both indirectly, through the gastrointestinal toxicity on the pregnant mothers, and directly upon the development of the foetus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethanol (96 per cent)</p><p>Sodium chloride</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ketesse solution for injection/ infusion must not be mixed in a small volume (e.g. in a syringe) with solutions of dopamine, promethazine, pentazocine, pethidine or hydroxyzine, as this will result in a precipitation of the solution.</p><p>The diluted solutions for infusion obtained as stated in Section 6.6 must not be mixed with promethazine or pentazocine.</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in Section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5 years.
After dilution according to directions given in Section 6.6., the diluted solution, provided it is adequately protected from natural daylight, has been shown to be chemically stable for 24 hours, when stored at 25 °C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Keep the ampoules in the outer carton in order to protect it from the light.</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I glass coloured ampoules containing 2 ml of Solution for injection/ infusion.</p><p>Packs containing: 1, 5, 6, 10, 20, 50 or 100 ampoules. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ketesse solution for injection/ infusion has shown to be compatible when mixed in small volumes (e.g. in a syringe) with injectable solutions of heparin, lidocaine, morphine and theophylline.</p><p>For administration as intravenous infusion the content of one ampoule (2 ml) of Ketesse solution for injection/ infusion should be diluted in a volume of 30 to 100 ml of normal saline, glucose or Ringer lactate solution. The solution should be diluted aseptically and protected from natural daylight (see also section 6.3). The diluted solution is a clear solution.</p><p>Ketesse Solution for injection/ infusion, diluted in a volume of 100 ml of normal saline or glucose solution has shown to be compatible with the following medicinal products: dopamine, heparin, hydroxyzine, lidocaine, morphine, pethidine and theophylline.</p><p>No sorption of the active ingredient has been found when diluted solutions of Ketesse solution for injection/ infusion have been stored in plastic bags or administration devices made of Ethyl Vinyl Acetate (EVA), Cellulose Propionate (CP), Low Density PolyEthylene (LDPE) and PolyVinyl Chloride (PVC).</p><p>Ketesse solution for injection/ infusion is for single use only and any unused solution should be discarded. Prior to administration, the solution should be inspected visually to make sure it is clear and colourless: it should not be used if particulate matter is observed.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Menarini International Operations Luxembourg S.A.,
1 Avenue de La Gare, L-1611 Luxembourg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>